ClinicalTrials.gg
CompletedNCT04849650Updated Dec 13, 2021

PK Study of IV and Oral Amisulpride in Subjects With Severe Renal Impairment

A Phase 1 interventional study of Amisulpride IV and Amisulpride Oral Tablet in Renal Disease, End Stage, sponsored by Acacia Pharma Ltd. Completed at 1 site in United States. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-12-13.

Sponsored by Acacia Pharma Ltd · Phase 1, Interventional, and Basic science

How we know

From the registry’s dates

  • Primary completion was Oct 2021, 5 years ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
12
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 765 studies in Kidney Failure, Chronic with a site in United States — 65 open to participants now, 96 under way, 9 of them phase 3. Kidney Failure, Chronic · United States.

Enrollment
520th of 638
12 · median 48
Started
2021
with 30 others
Phase 1
89 of 765
8 open now
Registered
626th of 765
by date

Among the 765 studies in Kidney Failure, Chronic with a site in United States, this one is the 520th largest by enrollment of the 638 interventional ones that give a count, is one of 31 that started in 2021, is one of 89 in phase 1, and was the 626th registered.

Kidney Failure, Chronic

2,115 studies on the registry are indexed under Kidney Failure, Chronic; 277 are open to participants now.

Browse Kidney Failure, Chronic studies →

Open to participants now

65 of the 765 studies in Kidney Failure, Chronic with a site in United States are open now. Recruiting first, the newest first:

60 more — sign in →

All 65 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 170 Kidney Failure, Chronic studies recruiting now, 109 (64%) set no upper age limit and 32 (19%) stop at 75 or younger; 18 take children under 18; 22 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 765 studies in Kidney Failure, Chronic with a site in United States, or all of them as a file.
02

Study summary

The aim of the study is to understand how Amisulpride is taken up and distributed around the body and how quickly it is eliminated, when given by mouth and into a vein in adults with severe kidney disease. In addition it is important to understand how well tolerated Amisulpride is in this patient population. Healthy adults will be studied to provide a comparison.

Read the detailed description

This will be an open-label, non-randomised, pharmacokinetic study in

  • 6 adult subjects with severe renal impairment and end-stage renal disease (i.e., eGFR \< 30 mL/min/1.73 m2) without dialysis.
  • 6 matched healthy subjects (control group).

Each subject will be given a single dose of 10 mg IV Amisulpride, followed by a single dose of 10 mg oral Amisulpride given 24 hours later.

Subjects will be admitted to the clinic on Day -1. Dosing will start the following day (Day 1). Serial blood samples will be taken during Days 1-3 to assess the pharmacokinetics of Amisulpride. Subjects will remain in clinic over the duration of the study and will be discharged when the final blood sample is drawn on Day 3.

The tolerability /safety of Amisulpride will be assessed by clinical chemistry and haematology assessments, vital signs, electrocardiograms (ECG), physical examination and adverse event reporting.

03

Conditions studied

  • Renal Disease, End Stage
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion Criteria: Healthy Subjects

  1. Age 18 to 75 years of age at time of signing ICF.
  2. (BMI) between 18 and 38 kg/m2.
  3. Must be willing and able to communicate and participate in the whole study.
  4. Must provide written .
  5. Must agree to use an adequate method of
  6. Healthy as defined by:

    • The absence of illness and surgery within 4 weeks prior to dosing. Subjects vomiting within 24 hours pre-dose will be carefully evaluated for upcoming illness/disease. Inclusion pre-dosing is at the discretion of the Principal Investigator;
    • The absence of clinically significant history of neurological, endocrine, cardiovascular, pulmonary, hematological, immunologic, psychiatric, gastrointestinal, renal, hepatic (including cholecystectomy), and metabolic disease;
    • The absence of clinically significant history of lactic acidosis and severe hepatomegaly with steatosis;
    • The absence of history of suicidal tendency, disposition to seizures, state of confusion, or clinically relevant psychiatric diseases.
  7. Normal renal function, i.e., or ≥ 90 mL/min/1.73 m2 as calculated using the MDRD4 or Cockcroft-Gault equation; at the Principal Investigator's discretion, 24 hour creatinine clearance may be conducted to determine renal function.
  8. Matched to subjects with severe renal impairment for gender, age (± 10 years), and BMI (± 15%) to the extent possible.

Inclusion Criteria: Renal Impaired Subjects

  1. Age 18 to 75 years of age at time of signing ICF.
  2. Body mass index (BMI) between 18 and 38 kg/m2.
  3. Must be willing and able to communicate and participate in the whole study.
  4. Must provide written informed consent.
  5. Must agree to use an adequate method of contraception
  6. A diagnosis of renal impairment that has been stable, without significant change in overall disease status in the 3 months prior to screening as determined by the Principal Investigator, with no requirement for dialysis, and an eGFR at screening \< 30 mL/min/1.73 m2 calculated using the MDRD4 equation.

Exclusion Criteria: Healthy Subjects

  1. Subjects who have received any IMP in a clinical research study within the 30 days prior to IMP administration on this study.
  2. Subjects who are study site, CRO or sponsor employees, or immediate family members of a study site, CRO or sponsor employee.
  3. Subjects who have previously been enrolled in this study.
  4. Women who are pregnant or breastfeeding.
  5. Subjects who have received amisulpride for any indication within the 30 days prior to dosing.
  6. Allergy to amisulpride or any of the of amisulpride.
  7. History of any drug or alcohol abuse in the 2 years prior to screening.
  8. Regular alcohol consumption >21 units per week in the 6 months prior to screening.
  9. Subjects who do not have suitable veins for multiple venepunctures/cannulation as assessed by the investigator at screening.
  10. History of epilepsy in the 5years prior toscreening.
  11. History of clinically significant syncope.
  12. Family history of sudden death.
  13. Family history of premature cardiovascular death.
  14. Clinically significant history or family history of congenital long syndrome (e.g.

    Romano-Ward syndrome, Jervell and Lange-Nielson syndrome) or Brugada's syndrome.

  15. History of clinically significant arrhythmias or ischaemic heart disease (especially ventricular arrhythmias, atrial fibrillation (AF), recent conversion from AF or coronary spasm).
  16. Conditions predisposing the volunteer to electrolyte imbalances (e.g. altered nutritional states, chronic vomiting, anorexia nervosa, bulimia nervosa).
  17. Clinically significant abnormal biochemistry,haematology or urinalysis at screening as judged by the investigator
  18. Positive drugs of abuse test result
  19. Positive surface antigen (HBsAg), virus antibody (HCV Ab) or (HIV) results at screening.
  20. Donation of plasma within 7 days prior to dosing. Donation or loss of blood (excluding volume drawn at screening or menses) of 50 mL to 499 mL of blood within 30 days, or more than 499 mL within 56 days prior to the dosing.
  21. Subjects who are taking, or have taken, any prescribed or over-the-counter drug (other than 2,000 mg per day acetaminophen) or herbal remedies in the 14 days before IMP administration
  22. Administration of a biological product in the context of a clinical research study within 90 days prior to dosing, or concomitant participation in an study involving no drug or device administration.
  23. Failure to satisfy the investigator of fitness to participate for any other reason.

Exclusion Criteria: Renal Impaired Subjects

  1. Subjects who have received any IMP in a clinical research study within the 30 days prior to IMP administration on this study.
  2. Subjects who are study site, CRO or sponsor employees, or immediate family members of a study site, CRO or sponsor employee.
  3. Subjects who have previously been enrolled in this study.
  4. Women who are pregnant or breastfeeding.
  5. Subjects who have received amisulpride for any indication within the 30 days prior to dosing.
  6. Allergy to amisulpride or any of the excipients of amisulpride.
  7. History of any drug or alcohol abuse in the 2 years prior to screening.
  8. Regular alcohol consumption >21 units per week in the 6 months prior to screening.
  9. Subjects who do not have suitable veins for multiple venepunctures/cannulation as assessed by the investigator at screening.
  10. History of epilepsy in the 5years prior to screening.
  11. History of clinically significant syncope.
  12. Family history of sudden death.
  13. Family history of premature cardiovascular death.
  14. Clinically significant history or family history of congenital long QT syndrome (e.g.

    Romano-Ward syndrome, Jervell and Lange-Nielson syndrome) or Brugada's syndrome.

  15. History of clinically significant arrhythmias or unstable ischaemic heart disease (especially ventricular arrhythmias, atrial fibrillation (AF), recent conversion from AF or coronary spasm).
  16. Positive drugs of abuse test result, unless caused by a documented prescription drug.
  17. Positive hepatitis B surface antigen (HBsAg), hepatitis C virus antibody (HCV Ab) or human immunodeficiency virus (HIV) results at screening.
  18. Donation of plasma within 7 days prior to dosing. Donation or loss of blood (excluding volume drawn at screening or menses) of 50 mL to 499 mL of blood within 30 days, or more than 499 mL within 56 days prior to the dosing.
  19. Administration of a biological product in the context of a clinical research study within 90 days prior to dosing, or concomitant participation in an investigational study involving no drug or device administration.
  20. Failure to satisfy the investigator of fitness to participate for any other reason.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
12 participants (actual)

Study arms

  • Experimental
    Renal Impairment Subjects

    10mg dose of IV Amisulpride, followed 24 hours by a 10mg oral dose of Amisulpride

    Drug: Amisulpride IV · Drug: Amisulpride Oral Tablet

  • Experimental
    Healthy Subjects

    10mg dose of IV Amisulpride, followed 24 hours by a 10mg oral dose of Amisulpride

    Drug: Amisulpride IV · Drug: Amisulpride Oral Tablet

Interventions

06

What researchers measure

Primary outcomes

  1. PK: Amisulpride plasma exposure (AUC) after a single IV dose

    Amisulpride plasma exposure after a single IV dose measured as the area under the concentration-time curve (AUC) between study drug administration and the time at which the following-day oral dose of Amisulpride is given

    Time frame: 24 hours

Secondary outcomes

  1. PK: Amisulpride plasma exposure (AUC) after a single oral dose

    Amisulpride plasma exposure after a single oral dose measured as the area under the concentration-time curve (AUC) from study drug administration extrapolated to infinity

    Time frame: 24 hours

  2. PK: Cmax

    Peak plasma concentration (Cmax), for both a single IV and single oral dose.

    Time frame: 24 hours

  3. PK: Tmax

    Time at which peak plasma concentration achieved (Tmax) for both a single IV and single oral dose.

    Time frame: 24 hours

  4. PK: T1/2

    Half-life (T1⁄2) of both a single IV and single oral dose.

    Time frame: 24 hours

  5. PK: Clearance

    Clearance of both a single IV and single oral dose.

    Time frame: 24 hours

  6. PK: Vd

    Volume of distribution (Vd) of both a single IV and single oral dose.

    Time frame: 24 hours

  7. Safety: AE

    Frequency and severity of treatment-emergent adverse events

    Time frame: From first study drug administration until discharge (4 days)

07

Study locations

1 site
  • Panax Clinical Research
    Miami Lakes, Florida 33014, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2021 to primary completion in Oct 2021, 4 months.

Of 46 industry-sponsored phase 1 interventional studies under Kidney Failure, Chronic, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 16. This study's 4 months is below that.

Counting every sponsor, half of 67 studies reached it within 12 months; a quarter within 5 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 14, 2021
First posted
Apr 19, 2021
StartActual
Jun 3, 2021
Primary completionActual
Oct 30, 2021
CompletionActual
Oct 30, 2021
Last update
Dec 13, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 13, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04849650
Lead sponsor
Acacia Pharma Ltd
Responsible party
Sponsor
First posted
Apr 19, 2021
Start date
Jun 3, 2021
Primary completion
Oct 30, 2021
Completion
Oct 30, 2021
Last update
Dec 13, 2021

Study contacts

Gabriel Fox, MD
study director · Chief Medical Officer

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Amisulpride

Start the discussion